


Glycy coumarin

Cat. No.:	HY-N4113		
CAS No.:	94805-82-0		
Molecular Formula:	C ₂₁ H ₂₀ O ₆		
Molecular Weight:	368.38		
Target:	Keap1-Nrf2; AMPK		
Pathway:	NF-κB; Epigenetics; PI3K/Akt/mTOR		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (678.65 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.7146 mL	13.5729 mL	27.1459 mL
		5 mM	0.5429 mL	2.7146 mL	5.4292 mL
10 mM		0.2715 mL	1.3573 mL	2.7146 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.65 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.08 mg/mL (5.65 mM); Suspended solution; Need ultrasonic				

BIOLOGICAL ACTIVITY

Description	Glycy coumarin is a potent antispasmodic agent. Glycy coumarin is a major bioactive coumarin of licorice and exhibits antispasmodic activity. Glycy coumarin also has hepatoprotective effect. Glycy coumarin can be used for the research of abdominal pain and liver diseases ^{[1][2]} .
In Vitro	Glycy coumarin, (25 μM; 24 h) combining with ABT-737 (12.5 μM) synergistically, induces cell death in multiple types of liver cancer cell HepG2 ^[2] . Glycy coumarin is highly effective against alcoholic liver disease, nonalcoholic fatty liver disease, acetaminophen-induced hepatotoxicity, and liver cancer through mechanisms involved in activation of Nrf2 antioxidant system, stimulation of AMPK-mediated energy homeostasis, induction of autophagy degradation process, and inhibiting oncogenic kinase T-lymphokine-activated killer cell-originated protein kinase activity ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	HepG2, SMMC-7721, and Huh-7
Concentration:	10, 20, 25, 30, and 40 μ M
Incubation Time:	24 hours
Result:	Induced cell death in multiple types of liver cancer cell lines in a dose-dependent manner.

In Vivo

Glycycomarin (30 μ M-0.3 nM; 5 min) has an inhibitory effect on smooth muscle contraction induced by various types of stimulants through the inhibition of PDEs, especially isozyme 3, followed by the accumulation of intracellular cAMP^[1]. Glycycomarin (10 mg/kg; i.p.; once daily for 4 d) enhances tumor growth inhibition in HepG2 xenograft model in mice and shows synergistical effect with [ABT-737](#) (HY-50907)^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male ICR mice (aged 6 weeks, weight 25-30 g) ^[1]
Dosage:	30 μ M-0.3 nM, 5 min
Administration:	
Result:	Inhibited the contraction induced by various types of stimulants, such as CCh, KCl, BaCl ₂ , and A23187 (calcium ionophore III). Enhanced the relaxation induced by forskolin on CCh-evoked contraction and also enhances the relaxation effect of rolipram. Associated with dose-dependent accumulation of cAMP.

Animal Model:	HepG2 cancer cells xenograft model in male BALB/c athymic nude mice (6-7 weeks old) ^[2]
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; once daily for 4 days; ABT-737 group was given 100 mg/kg i.p.
Result:	Inhibited tumor growth and resulted a reduction of the final tumor weight by 17%.

REFERENCES

[1]. Yuji Sato, et al. Glycycomarin from Glycyrrhizae Radix acts as a potent antispasmodic through inhibition of phosphodiesterase 3. *J Ethnopharmacol.* 2006 May 24;105(3):409-14.

[2]. Enxiang Zhang, et al. Protective effects of glycycomarin on liver diseases. *Phytother Res.* 2020 Jun;34(6):1191-1197.

[3]. Zhang E, et al. Glycycomarin Sensitizes Liver Cancer Cells to ABT-737 by Targeting De Novo Lipogenesis and TOPK-Survivin Axis. *Nutrients.* 2018 Mar 15;10(3):353.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA